Close Menu

NEW YORK — PerkinElmer said on Monday that its first quarter 2020 revenues and EPS are expected to be below previous company estimates on softness in the China market.

The Waltham, Massachusetts-based firm had said in January during its fourth quarter and full-year 2019 earnings announcement that revenues for Q1 2020 would be $700 million, while EPS from continuing operations were anticipated to be $.33. Adjusted EPS from continuing operations were estimated at $.70.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Science reports that Science Foundation Ireland is seeking annual budget increases.

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.